233 related articles for article (PubMed ID: 36960712)
1. GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model.
Dufu K; Alt C; Strutt S; Partridge J; Tang T; Siu V; Liao-Zou H; Rademacher P; Williams AT; Muller CR; Geng X; Pochron MP; Dang AN; Cabrales P; Li Z; Oksenberg D; Cathers BE
Br J Haematol; 2023 Jul; 202(1):173-183. PubMed ID: 36960712
[TBL] [Abstract][Full Text] [Related]
2. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
[TBL] [Abstract][Full Text] [Related]
3. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.
Schroeder P; Fulzele K; Forsyth S; Ribadeneira MD; Guichard S; Wilker E; Marshall CG; Drake A; Fessler R; Konstantinidis DG; Seu KG; Kalfa TA
J Pharmacol Exp Ther; 2022 Mar; 380(3):210-219. PubMed ID: 35031585
[TBL] [Abstract][Full Text] [Related]
4. GBT440 improves red blood cell deformability and reduces viscosity of sickle cell blood under deoxygenated conditions.
Dufu K; Patel M; Oksenberg D; Cabrales P
Clin Hemorheol Microcirc; 2018; 70(1):95-105. PubMed ID: 29660913
[TBL] [Abstract][Full Text] [Related]
5. MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease.
Demers M; Sturtevant S; Guertin KR; Gupta D; Desai K; Vieira BF; Li W; Hicks A; Ismail A; Gonçalves BP; Di Caprio G; Schonbrun E; Hansen S; Musayev FN; Safo MK; Wood DK; Higgins JM; Light DR
Blood Adv; 2021 Mar; 5(5):1388-1402. PubMed ID: 33661300
[TBL] [Abstract][Full Text] [Related]
6. Voxelotor improves red blood cell functionality in children with sickle cell anaemia: An ancillary study of the HOPE-KIDS 1 trial.
Chonat S; Fields E; Baratz H; Watt A; Pochron M; Dixon S; Tonda M; Brown C; Archer D
EJHaem; 2024 Feb; 5(1):125-130. PubMed ID: 38406531
[TBL] [Abstract][Full Text] [Related]
7. FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice.
Shrestha A; Chi M; Wagner K; Malik A; Korpik J; Drake A; Fulzele K; Guichard S; Malik P
Blood Adv; 2021 May; 5(9):2385-2390. PubMed ID: 33944896
[TBL] [Abstract][Full Text] [Related]
8. Model-informed drug development of voxelotor in sickle cell disease: Exposure-response analysis to support dosing and confirm mechanism of action.
Green ML; Savic RM; Tonda M; Jorga K; Washington CB
CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):698-710. PubMed ID: 35447017
[TBL] [Abstract][Full Text] [Related]
9. The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell Disease.
Nader E; Romana M; Connes P
Front Immunol; 2020; 11():454. PubMed ID: 32231672
[TBL] [Abstract][Full Text] [Related]
10. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells.
Nakagawa A; Ferrari M; Schleifer G; Cooper MK; Liu C; Yu B; Berra L; Klings ES; Safo RS; Chen Q; Musayev FN; Safo MK; Abdulmalik O; Bloch DB; Zapol WM
Mol Pharm; 2018 May; 15(5):1954-1963. PubMed ID: 29634905
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry.
Rab MAE; van Oirschot BA; Bos J; Kanne CK; Sheehan VA; van Beers EJ; van Wijk R
J Vis Exp; 2019 Nov; (153):. PubMed ID: 31762454
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Evaluation of Allosteric Effectors for Hemoglobin.
Enakaya NA; Jefferson A; Chew-Martinez D; Matthews JS
Acc Chem Res; 2023 Jun; 56(11):1279-1286. PubMed ID: 36946781
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide reduces sickle hemoglobin polymerization: potential role of nitric oxide-induced charge alteration in depolymerization.
Ikuta T; Thatte HS; Tang JX; Mukerji I; Knee K; Bridges KR; Wang S; Montero-Huerta P; Joshi RM; Head CA
Arch Biochem Biophys; 2011 Jun; 510(1):53-61. PubMed ID: 21457702
[TBL] [Abstract][Full Text] [Related]
14. Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease.
Xu JZ; Vercellotti GM
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):107-113. PubMed ID: 38066891
[TBL] [Abstract][Full Text] [Related]
15. PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease.
Gopalsamy A; Aulabaugh AE; Barakat A; Beaumont KC; Cabral S; Canterbury DP; Casimiro-Garcia A; Chang JS; Chen MZ; Choi C; Dow RL; Fadeyi OO; Feng X; France SP; Howard RM; Janz JM; Jasti J; Jasuja R; Jones LH; King-Ahmad A; Knee KM; Kohrt JT; Limberakis C; Liras S; Martinez CA; McClure KF; Narayanan A; Narula J; Novak JJ; O'Connell TN; Parikh MD; Piotrowski DW; Plotnikova O; Robinson RP; Sahasrabudhe PV; Sharma R; Thuma BA; Vasa D; Wei L; Wenzel AZ; Withka JM; Xiao J; Yayla HG
J Med Chem; 2021 Jan; 64(1):326-342. PubMed ID: 33356244
[TBL] [Abstract][Full Text] [Related]
16. A non-electrolyte haemolysis assay for diagnosis and prognosis of sickle cell disease.
Milligan C; Rees DC; Ellory JC; Osei A; Browning JA; Hannemann A; Gibson JS
J Physiol; 2013 Mar; 591(6):1463-74. PubMed ID: 23297308
[TBL] [Abstract][Full Text] [Related]
17. Nitrite decreases sickle hemoglobin polymerization in vitro independently of methemoglobin formation.
Almeida LEF; Smith ML; Kamimura S; Vogel S; de Souza Batista CM; Quezado ZMN
Toxicol Appl Pharmacol; 2023 Aug; 473():116606. PubMed ID: 37336294
[TBL] [Abstract][Full Text] [Related]
18. VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions.
Abdulmalik O; Pagare PP; Huang B; Xu GG; Ghatge MS; Xu X; Chen Q; Anabaraonye N; Musayev FN; Omar AM; Venitz J; Zhang Y; Safo MK
Sci Rep; 2020 Nov; 10(1):20277. PubMed ID: 33219275
[TBL] [Abstract][Full Text] [Related]
19. Increased hemoglobin affinity for oxygen with GBT1118 improves hypoxia tolerance in sickle cell mice.
Dufu K; Williams AT; Muller CR; Walser CM; Lucas A; Eaker AM; Alt C; Cathers BE; Oksenberg D; Cabrales P
Am J Physiol Heart Circ Physiol; 2021 Aug; 321(2):H400-H411. PubMed ID: 34213392
[TBL] [Abstract][Full Text] [Related]
20. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
Ferrone FA
Br J Haematol; 2016 Aug; 174(4):499-500. PubMed ID: 27410726
[No Abstract] [Full Text] [Related]
[Next] [New Search]
